Cosmos Health Plans $100M Stock Offering

TL;DR

Cosmos Health filing for $100M stock raise, buying AI drug platform.

AI Summary

Cosmos Health Inc. filed an S-1 form on October 28, 2024, detailing a proposed offering of 300,000,000 shares of common stock. The company aims to raise up to $100,000,000 from this offering. The filing also mentions a promissory note maturing on March 25, 2025, which is interest-free and related to an asset purchase agreement for an AI-powered drug repurposing platform.

Why It Matters

This S-1 filing indicates Cosmos Health is seeking significant capital, potentially to fund its AI-driven drug repurposing platform acquisition and further business development.

Risk Assessment

Risk Level: high — The company is seeking a substantial amount of capital through a stock offering, which can be dilutive and carries inherent market risks.

Key Numbers

• $100.0M — Proposed Offering Size (The maximum capital Cosmos Health Inc. aims to raise through the sale of common stock.)
• 300.0M — Shares Offered (The total number of common stock shares intended for sale in the offering.)
• March 25, 2025 — Promissory Note Maturity (The date by which an interest-free promissory note related to an asset acquisition must be settled.)

Key Players & Entities

• Cosmos Health Inc. (company) — Filer of the S-1 registration statement.
• October 28, 2024 (date) — Date of the S-1 filing.
• $100,000,000 (dollar_amount) — Maximum amount to be raised from the proposed stock offering.
• 300,000,000 (dollar_amount) — Number of common stock shares proposed to be offered.
• March 25, 2025 (date) — Maturity date of the interest-free promissory note.
• October 9, 2023 (date) — Date of the Asset Purchase, Sale and Transfer Agreement.

FAQ

Key Financial Figures

• $0.001 — up to 9,748,252 shares of Common Stock, $0.001 par value, of Cosmos Health Inc. (the "
• $0.8701 — e Company the reduced exercise price of $0.8701 per share; - In consideration for exe
• $0.95 — New Warrants have an exercise price of $0.95 per share, a premium to the closing pri
• $9,260,839 — we may receive gross proceeds of up to $9,260,839 from the issuance of New Warrant Shares
• $0.77 — price of the common stock on NASDAQ was $0.77. Investing in our securities is highly
• $11.50 — ber 21, 2022, with an exercise price of $11.50 per share (each a "Warrant Share") and
• $2.75 — uly 21, 2023, with an exercise price of $2.75 per share and expire 5.5 years from the
• $1.45 — e New Warrants are fully exercisable at $1.45 per share for a five-year period commen

Filing Documents

• cosm_s1.htm (S-1) — 3975KB
• cosm_ex51.htm (EX-5.1) — 12KB
• cosm_ex231.htm (EX-23.1) — 3KB
• cosm_ex232.htm (EX-23.2) — 4KB
• cosm_ex107.htm (EX-FILING FEES) — 37KB
• cosm_ex231img1.jpg (GRAPHIC) — 3KB
• cosm_s1img4.jpg (GRAPHIC) — 3KB
• cosm_s1img3.jpg (GRAPHIC) — 7KB
• cosm_ex232img4.jpg (GRAPHIC) — 2KB
• cosm_ex232img3.jpg (GRAPHIC) — 7KB
• 0001477932-24-006693.txt ( ) — 15880KB
• cosm-20240630.xsd (EX-101.SCH) — 137KB
• cosm-20240630_lab.xml (EX-101.LAB) — 728KB
• cosm-20240630_cal.xml (EX-101.CAL) — 91KB
• cosm-20240630_pre.xml (EX-101.PRE) — 653KB
• cosm-20240630_def.xml (EX-101.DEF) — 455KB
• cosm_s1_htm.xml (XML) — 2832KB

USE OF PROCEEDS

USE OF PROCEEDS 26 MARKET PRICE OF OUR COMMON STOCK 26

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 27

BUSINESS

BUSINESS 45 MANAGEMENT 55

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 60 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 63 PRINCIPAL SHOCKHOLDERS 64 WARRANT INDUCEMENT OFFER AND SELLING SHAREHOLDER 65 PLAN OF DISTRIBUTION 67 DESCRIPTION OF THE NEW WARRANT SHARES 68 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES 70 LEGAL MATTERS 76 EXPERTS 76 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 2 Table of Contents ADDITIONAL INFORMATION You should rely only on this prospectus, the documents incorporated or deemed to be incorporated by reference herein or therein, and any free writing prospectus prepared by us or on our behalf. We have not authorized anyone to provide you with information different than that contained or incorporated by reference in this prospectus and any free writing prospectus that we have authorized for use in connection with this Offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information appearing in this prospectus, the documents incorporated by reference herein, and in any free writing prospectus that we have authorized for use in connection with this Offering is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference herein, and any free writing prospectus that we have authorized for use in connection with this Offering in their entirety before making an investment decision. We are offering to sell, and are seeking offers to buy, the Shares only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus and the offering of the Shares in certain jurisdictions or to certain persons within such jurisdictions may be restricted by law. Persons outside the United States who come into possession of thi

View Full Filing

View this S-1 filing on SEC EDGAR